The transthyretin amyloidosis (ATTR) treatment market is experiencing robust growth, driven by advancements in therapies, increasing diagnosis rates, and the aging global population. Estimated at USD 6.94 billion in 2024, the market is expected to reach USD 20.35 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.60% from 2025 to 2033. This growth is propelled by the introduction of novel RNA-based therapies and combination treatments, offering improved patient outcomes and more effective management of ATTR.
Study Assumption Years:
- Base Year: 2024
- Historical Year: 2019-2024
- Forecast Year: 2025-2033
Transthyretin Amyloidosis Treatment Market Key Takeaways:
- Market Size in 2024: USD 6.94 billion
- Market Forecast in 2033: USD 20.35 billion
- CAGR (2025-2033): 11.60%
- North America dominates the transthyretin amyloidosis treatment market with a share of over 46.3% in 2024.
- Advancements in RNA-based therapies, such as patisiran and vutrisiran, are crucial for growth.
- The rising geriatric population is expected to increase demand for ATTR treatments.
- Innovative treatments targeting the root causes of ATTR are transforming the landscape.
What Are the Major Growth Factors Driving the Transthyretin Amyloidosis Treatment Market?
Technological Advancements in RNA-Based Therapies
RNA-based methods are revolutionizing ATTR treatment by addressing the genetic underpinnings of the disease. From patisiran to vutrisiran, such drugs are silencing defective genes producing transthyretin proteins. Clinical evidence for this approach's clear benefit includes one study that noted a 28% reduction in deaths among patients administered vutrisiran. This trend is likely to expand, establishing RNA-based treatment as a pillar for future therapies targeting ATTR.
Regulatory Support and Incentives
Regulatory agencies, especially the FDA in the U.S., are important in paving the path for ATTR treatment's development. Drug approvals like the one for BridgeBio's acoramidis show the increasing attention given to rare diseases. Incentives, such as orphan drug designation and fast-track review, create an environment that encourages pharmaceutical companies to develop novel therapies for ATTR. This regulatory context is expected to sustain the momentum of this market and continued innovation.
Demand for Personalized Medicine
The movement toward personalized medicine is now strongly influencing the management of ATTR. Genetic tests identify specific genetic mutations involved in the disease, and therefore provide opportunities for customized treatment that would yield improved outcomes for patients. The trend toward personalized therapies will encourage more sophisticated, precision-based treatments, thus furthering the growth of the ATTR treatment market.
Market Segmentation:
By Therapy:
- Targeted Therapy
- Vyndaqel/Vyndamax: These are FDA-approved therapies that stabilize transthyretin proteins, preventing amyloid deposits.
- Onpattro: An RNA interference-based drug targeting the root cause of ATTR.
- Amvuttra: A long-acting siRNA therapy designed for ATTR-CM and polyneuropathy.
- Tafamidis: Another targeted therapy stabilizing transthyretin to slow disease progression.
By Type:
- Wild-type ATTR
- The most common form, associated with aging, where transthyretin proteins misfold and form amyloid deposits.
- Hereditary ATTR
- A genetically inherited form of the disease, often presenting with more severe symptoms and requiring specialized treatments.
By Disease:
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- A cardiac manifestation of ATTR, characterized by amyloid deposits in the heart muscle.
- Transthyretin Amyloid Polyneuropathy (ATTR-PN)
- A neurological form affecting peripheral nerves and leading to significant disability.
By Distribution Channel:
- Hospital Pharmacies
- A primary source for dispensing medications directly to patients undergoing treatment in medical settings.
- Retail Pharmacies
- Provide patients with outpatient access to ATTR treatments.
- Online Pharmacies
- Increasingly popular due to the convenience of home delivery for long-term treatments.
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
What Are the Key Regional Insights in the Transthyretin Amyloidosis Treatment Market?
North America occupies about 46.3% of the market share globally. It is the largest market in terms of ATTR treatments in 2024. Increasing prevalence of ATTR among the aging populations along with approval of novel therapies serve as major growth drivers for this region. The United States market, in particular, benefits from regulatory support and significant investment in pharmaceutical R&D to its advantage for the accelerated development of more efficacious treatment modalities.
What Are the Recent Developments in the Transthyretin Amyloidosis Treatment Market?
The recent developments in the ATTR treatment market indicate an array of innovations continuing with RNA therapy-focused innovations. An example is the recent U.S. FDA approval for BridgeBio's acoramidis for the treatment of ATTR-CM in November 2024, giving patients a new disease-modifying option. Besides, clinical trials for combination therapy for patisiran and tafamidis suggest promising improvements in patient benefits, which expand interest in combination therapies.
Who Are the Key Players in the Transthyretin Amyloidosis Treatment Market?
Akcea Therapeutics, Inc, Alnylam Pharmaceuticals, Inc., AstraZeneca, BridgeBio, Inc., Intellia Therapeutics, Inc, Pfizer Inc, etc.
If you require any specific information that is not currently covered within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, considerations studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Comments
0 comment